Biofrontera speeds drug development through microdosing
<p>UK-based Xceleron, a pioneer in methods of accelerating drug development, is to carry out a Phase 0 microdose study with Biofrontera Bioscience, a developer of drugs for the treatment of dermatological and inflammatory diseases.</p>